Efficacy of hormonal and mental treatments with MMPI in FtM individuals: cross-sectional and longitudinal studies

Hiroyuki Oda* and Toshihiko Kinoshita

Abstract

Background: Cross-sex hormone treatment (CSHT) is an important option for gender dysphoria (GD) individuals to improve the quality of life. However, in Japan, sex reassignment surgery (SRS) and CSHT for GD had been discontinued until 1998 (over 30 years). After resumption, the number of GD individuals wishing treatment rapidly increased. On the other hand, the number of medical institutions available for evaluation was limited. For this reason, hormonal treatment has been administered to GD individuals requiring the prompt start of CSHT in the absence of mental health assessment by specialists. In this study, we examined the efficacy of CSHT and psychotherapy.

Methods: The participants were 155 female-to-male (FtM) individuals who consulted our gender identity clinic, and were definitively diagnosed. A cross-sectional study was conducted by dividing them into two groups: groups with and without CSHT on the initial consultation (Group CSHT: n = 53, Group no-CSHT: n = 102). In all participants, Minnesota Multiphasic Personality Inventory (MMPI) and blood hormone tests were performed on the initial consultation. In addition, CSHT was combined with psychotherapy for a specific period in Group no-CSHT, and FtM individuals in whom an additional MMPI test could be conducted (Group combined treatment (CT), n = 14) were enrolled in a longitudinal study.

Results: In the cross-sectional study, there was no significant difference on the MMPI test. In the longitudinal study, there were improvements in the clinical scales other than the Mf scale on the MMPI test. In Group CT, the D, Sc, and Si scale scores on the initial consultation were significantly higher than in Group CSHT. However, there was no clinical scale with a significantly higher value after the start of treatment. The Pd scale score was significantly lower.

Conclusions: CSHT improved mental health. Psychotherapy-combined CSHT may further improve it.

Trial registration: The study was reviewed and approved by the Ethics Committee of Kansai Medical University (A comprehensive treatment for gender dysphoria: No. 0314 registered date 10th December 2003), and was approved at UMIN000028102 on 6th July 2017 as retrospectively registered.

Keywords: Gender Dysphoria, Female-to-male individuals, Minnesota Multiphasic personality inventory (MMPI), Cross-sex hormonal treatment, Psychotherapy
**Background**

In Japan, gender dysphoria (GD) refers to a condition in which biological sex is not consistent with self-consciousness or self-recognition of gender [1]. In the International Statistical Classification of Diseases and Related Health Problems (ICD-10) [2] and Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) [3], diagnostic criteria are defined, and GD is internationally known. In 2013, the American Psychiatric Association changed the concept of diagnosis. As a result, although GD is included in DSM-5, GD was no longer Gender Identity “Disorder”. Recently, GD is not always related to severe comorbid psychiatric findings, and is better characterized by experience and discomfort associated with gender dysphoria.

On the other hand, formal epidemiologic studies on the incidence and prevalence of transsexualism specifically or transgender and gender nonconforming identities in general have not been conducted, and efforts to achieve realistic estimates are fraught with enormous difficulties [4, 5]. And, for various reasons, researchers who have studied incidence and prevalence have tended to focus on the most easily counted subgroup of gender nonconforming individuals: transsexual individuals who experience gender dysphoria and who present for gender-transition-related care at specialist gender identity clinics [6]. According to the report, the rate of male-to-female (MtF) individuals was 1/11,900 to 45,000, and that of female-to-male (FtM) individuals was 1/30,400 to 200,000 [7]. And some scholars have suggested that the prevalence is much higher, depending on the methodology used in the research [8].

In Japan, a survey was performed by the Special Committee for Gender Dysphoria of the Japanese Society of Psychiatry and Neurology in 2013, and the number of GD individuals who consulted a medical institution, complaining of GD, was estimated to be approximately 17,000. This number corresponds to 1/7000 in Japan. It is higher than the prevalence rate described by De Cuypere [6]. However considering indications by Olyslager & Conway [7], the actual number may be greater. Furthermore, the FtM-to-MtF ratio in Japan is 2.2:1 [3]. This ratio is different compared to some western country.

Concerning medical practice for GD, there are specific circumstances in Japan. In 1969, sex reassignment surgery (SRS) for MtF individuals was evaluated as guilty for the following reasons: evaluation for diagnosis was not performed, and informed consent regarding SRS was not obtained. However, SRS was misunderstood as violating the laws. As a result, not only SRS but also physical treatment, including CSHT, was officially avoided. In 1997, the “Guidelines for the Diagnosis and Treatment of GD” were published by the Japanese Society of Psychiatry and Neurology [9]. Strict criteria for evaluation and physical treatment indication were established so that a judgment of guilty might not be given again. In 1998, SRS was performed according to the guidelines. The guidelines in Japan were prepared with reference to the standards of care for the health of transsexual, transgender, and gender nonconforming people, 7th edition (SOC7) [4]. Currently, the 4th version has been announced [10].

Although medical practice for GD, which had been discontinued over approximately 30 years, was resumed, there are few physicians who can evaluate GD and make a definitive diagnosis or such medical institutions. GD individuals had to wait for 6 to 12 months until consultation at a gender identity clinic. To GD individuals requiring the prompt start of CSHT, hormonal treatment has been administered based on gynecologists’ or urologists’ evaluation at local clinics in the absence of assessment by mental health specialists. As a result, GD individuals who consulted our gender identity clinic

---

**Table 1 Classification (cross-sectional study)**

| First Visit | Psychotherapy | CSHT | MMPI |
|-------------|---------------|------|------|
| CSH T       | n = 53        | -    | +    | +    |
| no-CSHT     | n = 102       | -    | -    | +    |

---

**Table 2 Classification (longitudinal study)**

| CT     | n = 14 | First Visit | Psychotherapy | CSHT | MMPI |
|--------|--------|-------------|---------------|------|------|
|        |        | After Treatment | +     | +    | +    |

---

**Fig. 1** Intergroup comparison of testosterone levels. Normal range (Female: 0.13–0.69, Male: 2.07–7.61)
consisted of those who had not been evaluated and those in whom hormonal treatment was started without evaluation.

Recently, several studies in other countries evaluated the effects of hormonal treatment on FtM. The efficacy of CSHT was reviewed by Colizzi and Costa [11]. Concerning FtM, some studies assessed the quality of life (QOL) using the 36-Item Short Form Health Survey (SF-36) [12, 13], and others using the Social Anxiety and Distress Scale (SADS) and Hospital Anxiety and Depression Scale (HADS) [14] or using the Zung Self-rating Anxiety Scale (SAS), Zung Self-rating Depression Scale (SDS), and Symptom Checklist-90-R (SCL-90-R)(longitudinal study) [15] indicated that hormonal treatment seemed to have a positive effect on GD individuals’ mental health. This remains controversial, but many investigators supported the effects of hormonal treatment.

The Minnesota Multiphasic Personality Inventory (MMPI) involves many clinical scales, facilitating many-sided personality assessment. Therefore, it has been used for the psychological assessment of GD [16–26]. Several studies investigated CSHT using the MMPI [27–31]. However, no longitudinal study has compared changes before and after CSHT in FtM individuals using the MMPI.

In this study, the effects of assessment-free CSHT were initially examined. Subsequently, the effects of CSHT with evaluation and psychotherapy were investigated. As the number of MtF individuals was small, FtM individuals were adopted as participants. The participants were divided into two groups based on the presence or absence of CSHT, and its effects were evaluated based on the MMPI test results and blood hormone levels.

The protocol of this study was approved by the Ethics Review Board of Kansai Medical University. Written informed consent was obtained from all FtM individuals on the initial consultation after explaining that information on medical and psychological examinations may be published in academic journals.

**Methods**

Since 1999, Kansai Medical University Medical Center has been responsible for GD treatment. According to the guidelines in Japan, comprehensive treatment has been performed by a medical team consisting of psychiatrists, urologists, gynecologists, plastic surgeons, psychiatric social workers, clinical psychologists, and clerical employees [31].

The participants of this study were 183 FtM individuals who were definitively diagnosed at our gender identity clinic before the end of December 2008. The participants comprised our series. Informed consent regarding study participation was obtained from all participants. For diagnosis, it was confirmed that the participants met the diagnostic criteria for GID presented in the DSM-IV-TR [32], and that no participant denied the essential gender identity or wished to undergo SRS due to mental disorder such as schizophrenia. Definitive diagnoses were made by two psychiatrists based on a consistency in the results of evaluation.

Of the 183 FtM individuals, we analyzed 155 (mean age: 25.6 ± 5.9 years [15–43 years]), excluding 28 in whom hormone levels were measured before July 1, 2004 because hormone-measuring methods were changed on July 1, 2004. The 155 participants had

| Table 3 Correlations between testosterone/estradiol levels and the MMPI clinical scales |
|---------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|                                | Hs  | D   | Hy  | Pd  | Mf  | Pa  | Pt  | Sc  | Ma  | Si  |
| Testosterone levels            |     |     |     |     |     |     |     |     |     |     |
| CSHT                           | 0.821 | 0.803 | 0.424 | 0.532 | 0.947 | 0.665 | 0.917 | 0.789 | 0.435 | 0.453 |
| no-CSHT                        | 0.237 | 0.158 | 0.408 | 0.707 | 0.768 | 0.387 | 0.322 | 0.420 | 0.870 | 0.584 |
| Estradiol levels               |     |     |     |     |     |     |     |     |     |     |
| CSHT                           | 0.079 | 0.337 | 0.144 | 0.377 | 0.549 | 0.067 | 0.698 | 0.188 | 0.542 | 0.987 |
| no-CSHT                        | 0.254 | 0.037* | 0.064 | 0.062 | 0.962 | 0.241 | 0.023* | 0.268 | 0.475 | 0.286 |

* p < 0.05, () Pearson Correlation Coefficient
not undergone assessment or psychotherapy in other hospitals.

They were divided into two groups: FtM individuals who had received CSHT before the initial consultation at the gender identity clinic (Group CSHT) and those who had not received it (Group no-CSHT). In addition, in the latter, FtM individuals in whom CSHT was started in combination with psychotherapy (combined treatment) based on the results of evaluation after the start of outpatient care were assigned to Group CT.

Of the 155 FtM individuals, 53 comprised Group CSHT (mean age: 26.8 ± 6.0 years [17–43 years]), 102 comprised Group no-CSHT (mean age: 24.9 ± 5.8 years [15–41 years]) (Table 1), and 14 comprised Group CT (mean age: 23.9 ± 4.1 years [18–32 years]) (Table 2). There were no significant differences in the mean age among the 3 groups. Furthermore, there were no marked differences in the school period or working state based on the information obtained on consultations.

We conducted several psychological tests early after the initial consultation to assist a diagnosis and evaluate adaptability to physical treatment. In particular, the MMPI is a personality test with a questionnaire consisting of 383 items. This test requires approximately 1 h, but the current mental state can be simply evaluated using 10 clinical scales (hypochondriasis (Hs), depression (D), hysteria (Hy), psychiatric disease qualitative deviation (Pd), masculinity/femininity (Mf), paranoia (Pa), psychasthenia (Pt), schizophrenia (Sc), hypomania (Ma), and social introversion (Si) scales). Therefore, this test may also be important to obtain suggestions regarding the indication of treatment. Furthermore, the clinical scales include a scale regarding male and female sex (Mf scale), which is characteristic. Since the 1970’s, this scale has been used to evaluate the psychological properties of GD [33].

In addition to the MMPI test, the blood levels of testosterone and estradiol were measured as blood hormone levels on the initial consultation. In addition, in Group CT, the second MMPI test was conducted after performing CSHT for a specific period (519 ± 365 days) in parallel with psychotherapy.

To confirm the effects of previous CSHT, the blood levels of testosterone and estradiol on the initial consultation in Group CSHT were compared with those in Group no-CSHT. In addition, to evaluate the relationship between the hormone levels and mental state, we analyzed the relationship between the clinical scales of the MMPI and blood testosterone and estradiol levels in the same groups using Pearson’s test.

To evaluate the effects of CSHT, the MMPI clinical scale scores on the initial consultation were compared between Groups CSHT and no-CSHT using the Mann-Whitney U-test.

To evaluate the effects of starting CSHT during psychotherapy following assessment on the mental state, the MMPI clinical scale scores after a specific period of CSHT in Group CT were compared with those on the initial consultation using Wilcoxon’s coded rank test.

To examine the effects of CSHT with respect to the presence or absence of psychotherapy, the MMPI clinical scale scores on the initial consultation in Group CT were compared with those in Group CSHT using the Mann-Whitney U-test. In addition, the scores after the start of CSHT in Group CT (on the second MMPI test) were compared with those in Group CSHT.

Essentially, participants in whom hormonal treatment was started after the initial consultation should be randomly divided into two groups: CT and non-psychotherapy-combined groups, and the results should be compared. However, according to the guidelines in Japan, CSHT cannot be started in the absence of psychotherapy. Therefore, this study involved Group CSHT, in which CSHT had been performed before the initial consultation in the absence of psychotherapy. (Psychotherapy described in the guidelines in Japan refers to mental support, a review of real life experience (RLE), and assistance to improve the QOL in a new life).

### Results

With respect to hormone levels, the blood testosterone level in Group CSHT was significantly higher (Fig. 1), and the blood estradiol level was significantly lower (Fig. 2). Concerning the correlation between the hormone levels and MMPI clinical scales (Table 3), the blood testosterone level was not correlated with any clinical scale in Groups CSHT or no-CSHT. In Group CSHT, the blood estradiol levels were not correlated with any clinical scale, whereas in Group no-CSHT, the blood estradiol level was correlated with several clinical scales, including Hs, D, Hy, Pd, Mf, Pa, Pt, Sc, Ma, and Si.

### Table 4 Intergroup comparisons of the clinical scales

| Clinical Scales | Hs | D | Hy | Pd | Mf | Pa | Pt | Sc | Ma | Si |
|-----------------|----|---|----|----|----|----|----|----|----|----|
| Two-sided p value | 0.270 | 0.752 | 0.806 | 0.383 | 0.821 | 0.406 | 0.902 | 0.297 | 0.717 | 0.983 |

No significant differences were observed

### Table 5 Intergroup comparisons of the clinical scales

| Clinical Scales | Hs | D | Hy | Pd | Mf | Pa | Pt | Sc | Ma | Si |
|-----------------|----|---|----|----|----|----|----|----|----|----|
| Two-sided p value | 0.124 | 0.013* | 0.006* | 0.017* | 0.861 | 0.071 | 0.023* | 0.050 | 0.328 | 0.054 |

*p < 0.05
level was positively correlated with the D and Pt scales. In Group no-CSHT, it was not correlated with any clinical scale.

There were no significant differences in any MMPI clinical scale between Groups CSHT and no-CSHT (Table 4). After the start of hormonal treatment, improvements in the MMPI clinical scale scores, other than the Mf scale score, were achieved in comparison with the values on the initial consultation. In particular, there were significant improvements in the D, Hy, Pd, and Pt scale scores (Table 5) (Fig. 3).

When comparing the results on the initial consultation in Group CT with those in Group CSHT (Table 6), the D, Sc, and Si scale scores were significantly higher. When comparing the results of the second MMPI test in Group CT with those in Group CSHT (Table 7), the Pd scale score was significantly lower.

**Discussion**

CSHT is technically easier than surgery, and its cost is relatively inexpensive. For this reason, CSHT for FtM individuals is routinely performed to relieve psychiatric symptoms associated with gender dysphoria-related mental distress and acquire a better mental well-being. Therefore, its effects on the mental state should be particularly evaluated in detail.

We initially investigated the blood levels of hormones to evaluate the presence or absence of CSHT, and confirmed that the influence of hormone agents was strongly reflected in Group CSHT. The blood testosterone level was significantly higher (Fig. 1), and the estradiol level was significantly lower (Fig. 2). In particular, the median blood testosterone level exceeded the upper limit of the reference range in males, and the first quartile was twice as high as the upper limit of the reference range in males. Based on these results, we confirmed that CSHT had been performed in Group CSHT; an excessive dose of CSH may have been administered to some participants. Thus, there were marked CSHT-related changes in the hormone levels, but there were no significant differences in the MMPI clinical scale scores between Group CSHT and Group no-CSHT (Table 4). Concerning the correlation between the level of each hormone and mental state, the estradiol level was weakly correlated with the D and Pt scales, and there was no marked correlation (Table 3).

Previous cross-sectional [12–14, 30, 34–37] and longitudinal [15, 38–41] studies examined the relationship between CSHT and the mental health involving FtM individuals. Some cross-sectional studies [40, 41] reported the significant effects of CSHT in MtF individuals alone. However, in other studies, the significant effects of CSHT were also obtained in FtM individuals. Several studies compared FtM individuals receiving CSHT with those who had not received CSHT [12] or non-GD individuals [13] using the SF-36, and suggested a positive effect of hormone therapy on GD individuals’ QOL. A study evaluated GD individuals before SRS using the Social Self-Esteem Inventory (SSEI), Beck Depression Inventory (BDI), Subjective Quality of Life Analysis (SQUALA), and Global Assessment of Functioning scale (GAF), and reported that hormone therapy was less severe depression symptoms [34]. Another study evaluated GD individuals using the World Health Organization Quality of Life-shorter version (WHOQOL-BREF), and reported that CSHT was linked to a better self-reported QOL in GD [34]. Furthermore, another study compared GD individuals receiving CSHT with those who had not received it using the SADS and HADS, and reported its positive effects on social distress, anxiety, and depression [14]. Another study involving FtM individuals before SRS using the MMPI showed that CSHT improved psychopathology [30].

Several longitudinal studies demonstrated the efficacy of CSHT using the SAS, SDS, SCL-90-R, Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders I (SCID-I) [15], SCL-90-R, Psychosocial questionnaires [38], Dissociative Experiences Scale (DES) [39], blood cortisol level, Perceived Stress Scale (PSS) [40], expectancy list of mood and sexual interest (ELOMS), affect intensity measure (AIM), short anger situation questionnaire (ASQ), affective communication test (ACT), and premenstrual assessment form (PAF) [41].

**Table 6** Intergroup comparisons of the clinical scales

|        | Hs | D   | Hy  | Pd  | Mf  | Pa  | Pt  | Sc  | Ma  | Si  |
|--------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Two-sided p value | 0.400 | 0.034* | 0.342 | 0.487 | 0.699 | 0.058 | 0.115 | 0.046* | 0.430 | 0.006* |

*p < 0.05
In this study, there was no significant difference in any MMPI clinical scale score between Groups CSHT and no-CSHT. The results of previous cross-sectional studies suggest the positive effects of CSHT in FtM individuals [12–14, 30, 34, 36]. However, a previous study using the MMPI did not show any significant difference [37]. It was indicated that, when the MMPI clinical scale score was within the normal range, it did not reflect the influence of CSHT [37]. In addition, in Group CSHT, which was analyzed in this study, CSHT was started because FtM individuals could not wait until assessment at a gender identity clinic due to specific circumstances in Japan. CSHT may have improved the mental health from a state in which FtM individuals wished to start CSHT promptly to the level of Group no-CSHT in which FtM individuals could wait for a long period until consultation, thus leading to the absence of a significant difference between Groups CSHT and no-CSHT.

In Group CT, improvements in the clinical scale scores other than the Mf scale score were achieved after CSHT. In particular, there were significant improvements in the D, Hy, Pd, and Pt scale scores. In addition, the D, Sc, and Si scale scores on the initial consultation in Group CT were significantly higher than in Group CSHT, but the Pd scale score was significantly lower after treatment. This suggests that CSHT combined with psychotherapy improves the mental health. Although the efficacy of CSHT was confirmed, CSHT-related apparent masculinization may affect the FtM individuals’ relationships with others. Furthermore, the effects of CSHT are marked in FtM individuals, but it may stimulate aggression [41]. The combination of CSHT and psychotherapy, involving mental support and a review of RLE, as well as continuous assistance to improve the QOL in a new life, may have led to mental stability.

Concerning the Mf scale, Bonierbale et al. reported that the scale score in the CSHT group was significantly lower than in the no-CSHT group [30]. They indicated that CSHT have less need to assert themselves because of their bodies and their perception that their appearance is more in accordance with their stereotype [30]. On the other hand, our study did not show any significant difference between Groups CSHT and no-CSHT or before and after CSHT in Group CT. Briefly, CSHT did not influence the Mf scale score regardless of the presence or absence of psychotherapy. In Japan, SRS is a requirement for changing the sex in the family register; therefore, CSHT reduces body uneasiness, but, socially, the FtM individuals’ gender is female. This may not have contributed to a reduction in the assertion of being male, leading to the results differing from those reported by Bonierbale.

A mental health screening and/or assessment is needed for referral to hormonal treatment for GD [4, 10]. In contrast, psychotherapy – although highly recommended – is not a requirement [4]. In Japan, it is recommended that CSHT should be performed while continuing psychotherapy involving sympathy with psychological/social/physical stress and a review of RLE-related problems at working places/schools [10]. We previously reported that favorable results were obtained when performing CSHT in such a state [42]. The results of this study also suggest that, when performing CSHT in FtM individuals, further improvements may be achieved by evaluating the mental health and combining psychotherapy.

However, our study has a limitation: when performing CSHT, it was impossible to assign the participants to psychotherapy and psychotherapy-free groups and evaluate the results, because CSHT cannot be started in the absence of psychotherapy in accordance with the guidelines in Japan.

**Conclusions**

We examined the effects of CSHT and psychotherapy in FtM individuals using the MMPI through cross-sectional and longitudinal studies. In the cross-sectional study, we evaluated the results with respect to the presence or absence of CSHT. However, there were no significant differences in the MMPI clinical scale scores. In the longitudinal study, the combination of CSHT and psychotherapy significantly improved the MMPI clinical scale scores. CSHT improve mental health, and, when combined with psychotherapy, further improvements may be achieved.

**Abbreviations**

- ACT: Affective communication test
- AIM: Affect intensity measure
- ASQ: Short anger situation questionnaire
- BDI: Beck Depression Inventory
- CSHT: Cross-sex hormone treatment
- CT: Combined treatment
- D: Depression
- DES: Dissociative Experiences Scale
- DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, text revision
- ELOMS: expectancy list of mood and sexual interest
- FtM: Female-to-male
- GAF: Global Assessment of Functioning scale
- GD: Gender dysphoria
- GID: Gender identity disorder
- HADS: Hospital Anxiety and Depression Scale
- Hy: Hypochondriasis
- ICD-10: International Statistical Classification of Diseases and Related Health Problems
- Mf: Masculinity/Femininity
- MMPI: Minnesota Multiphasic Personality Inventory
- MA: Hypomania
- PAF: premenstrual assessment form
- Pd: Psychopathic Deviate
- PSS: Perceived Stress Scale
- Pt: Psychasthenia
- SADS: Social Anxiety and Distress Scale
- SAS: Zung Self-rating Anxiety Scale
- SCID-I: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders I
- SCL-90-R: Symptom Checklist-90-R
- SDS: Zung Self-rating Depression Scale
- SF-36: 36-Item Short Form Health Survey
- Si: Social Introversion
- SQUALA: Subjective Quality of Life

**Table 7 Intergroup comparisons of the clinical scales**

|        | Hs  | D   | Hy  | Pd  | Mf  | Pa  | Pt  | Sc  | Ma  | Si  |
|--------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Two-sided p. value | 0.688 | 0.562 | 0.066 | 0.010* | 0.804 | 0.474 | 0.276 | 0.932 | 0.142 | 0.208 |

*p < 0.05
Analysis: SRS: Sex reassignment surgery; SSBI: Social Self-Esteem Inventory; WHO-QOL-BREF: World Health Organization Quality of Life-shorter version.

Acknowledgements
We deeply appreciate Dr. Shinji Hosoda for providing advice and cooperation in preparing this paper. We also appreciate everyone who helped with this research.

Funding
This study was not supported by any funds.

Availability of data and materials
The data has been archived, with consent under the control of the authors. Raw data cannot be shared as participant permission to has not been granted to share the data freely.

Authors' contributions
HO designed this study, analyzed the data, and wrote the manuscript. TK advised throughout this study. In addition, TK supported document revision. HO helped with this research. TK supported document revision. HO designed this study, analyzed the data, and wrote the manuscript. TK helped with this research.

Ethics approval and consent to participate
The Ethics Committee of Kansai Medical University approved this study. All participants provided written informed consent to participate in this study.

Consent for publication
Not applicable.

Competing interests
Both authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 March 2017 Accepted: 6 July 2017
Published online: 17 July 2017

References
1. Yamaguchi T. Diagnosis of gender identity disorder: basic and clinical aspects of gender identity disorder. 2nd rev ed. Shinoh Igaku Shuppan: Tokyo; 2004.
2. World Health Organization. The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guideline. Geneva: World Health Organization; 1992.
3. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington: American Psychiatric Association; 2013.
4. WPATH (The World Professional Association for Transgender Health). The standards of care for the health of transsexual, transgender, and gender nonconforming people, 7th ed. 2010. http://www.wpath.org/.
5. Zucker KJ, Lawrence AA. Epidemiology of gender identity disorder: recommendations for the standards of care of the world professional Association for Transgender Health. International Journal of Transgenderism. 2000;11:8–18.
6. De Cuypere G, Van Hemelrijck M, Michel A, Carael B, Heylens G, Rubens R, Monstrey S. Prevalence and demography of transsexualism in Belgium. European Psychiatry. 2007;22:137–41.
7. Olyslager F, Conway L. On the calculation of the prevalence of transsexualism. Paper presented at the world professional Association for Transgender Health 20th international symposium. Chicago; Illinois; 2010.
8. Sato T, Saito K, et al. Estimated investigation of the number of GID. Japanese Journal of Gender Identity Disorder. 2014;7:3–5.
9. Special Committee for Gender Identity Disorder of the Japanese Society of Psychiatry and Neurology. Report and recommendations on gender identity. Seishin Shinkeigaku Zasshi. 1997;95:33–40.
10. Special Committee for Gender Identity Disorder of the Japanese Society of Psychiatry and Neurology. The guidelines for diagnosis and treatment for gender identity disorder. Seishin Shinkeigaku Zasshi. 2012;114:1250–66.
11. Costa R, Colizzi M. The effect of cross-sex hormonal treatment on gender dysphoria individuals’ mental health: a systematic review. Neuropsychiatr Dis Treat. 2016;12:1953–66.
12. Newfield E, Hart S, Dibble S, Kohler L. Female-to-male transgender quality of life. Qual Life Res. 2006;15:1447–57.
13. Gorin-Lazard A, Baumstark K, Boyer L, Maquigneau A, et al. Hormonal therapy associated with better quality of life in transsexuals?: a cross-sectional study. J Sex Med. 2012;9:531–41.
14. Gomez-Gil E, Zubiurre-Elorza L, Esteve I, et al. Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology. 2012;37:662–70.
15. Colizzi M, Costa R, Todarello O. Transsexual patients’ psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study. Psychoneuroendocrinology. 2014;39:65–73.
16. Beattie J. A psychological comparison of heterosexuals, transvestites, preoperative transsexuals, and postoperative transsexuals. J Nerv Ment Dis. 1985;173:358–65.
17. Hunt DD, Hampson JL. Follow-up of 17 biologic male transsexuals after sex-reassignment surgery. Am J Psychiatry. 1980;137:432–8.
18. Lothstein L. The aging gender dysphoria (transsexual) patient. Archives Sex Behav. 1979;8:431–44.
19. Tsoi W, Kok L, Long F. Male transsexualism in Singapore: a description of 56 cases. Br J Psychiatry. 1977;131:405–9.
20. Caron GR, Archer RP. MMPI and Rorschach characteristics of individuals approved for gender reassignment surgery. Assessment. 1997;7:229–41.
21. Cole CM, O’Boyle M, Emory LE, Meyer WJ. Comorbidity of gender dysphoria and other major psychiatric diagnoses. Archives Sex Behav. 1997;26:13–26.
22. Greenberg RP, Laurence L. A comparison of the MMPI results for psychiatric patients and male applicants for transsexual surgery. J Nerv Ment Dis. 1981;169:320–3.
23. Hunt DD, Carr JE, Hampson JL. Cognitive correlates of biologic sex and gender identity in transsexualism. Archives Sex Behav. 1981;1065–77.
24. Miach PP, Berah EF, Butcher JN, Rouse S. Utility of the MMPI-2 in assessing gender dysphoric patients. J Personality Assess. 2000;75:268–79.
25. Michel A, Ansemeau M, Legros JI, Pitchot W, Corpet JP, Mommont C. Comparisons of two groups of sex-change applicants based on the MMPI-2. Psychol Rep. 2002;91:333–40.
26. Tsuchima WT, Wedding D. MMPI results of male candidates for transsexual surgery. J Personality Assess. 1979;43:385–7.
27. Blanchard R, Clemmensen LH, Steiner BW. Gender reorientation and psychosocial adjustment in male-to-female transsexuals. Arch Sex Behav. 1993;12:503–9.
28. Leavitt F, Berger JC, Hoepner NA, Northrop G. Presurgical adjustment in male transsexuals with and without hormonal treatment. J Nerv Ment Dis. 1980;168(11):693–7. 22.
29. Gomez-Gil E, Vidal-Hagermeijer A, Manel Salamero-bar. MMPI-2 characteristics of transsexuals requesting sex reassignment: comparison of patients in Prehormonal and Presurgical phases. J Personality Assess. 2008; 80(4):368–74.
30. Bonierbe M, Baumstark K, Maquigneau A, et al. MMPI-2 profile of French transsexuals: the role of sociodemographic and clinical factors. A cross-sectional design Sci Rep. 2016;6:24281.
31. Oda H, Kitashiro A, Yamada K, et al. Efforts of gender clinic at Kansai medical university. Modern Physician. 2005;4:409–13.
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorder. 4th ed. Arlington: American Psychiatric Association; 2000.
33. Boileau M, Boyle M, Emory LE, Meyer WJ. Comorbidity of gender dysphoria and other major psychiatric diagnoses. Archives Sex Behav. 1997;26:13–26.
34. Gorin-Lazard A, Zubiurre-Elorza L, de Antonio IE, Guillamon A, Salamero M. Determinants of quality of life in Spanish transsexuals attending a gender unit before genital sex reassignment surgery. Qual Life Res. 2014;23(2):669–76.
35. Fishier AD, Castellì G, Bandini E, et al. Cross-sex hormonal treatment and body uneasiness in individuals with gender dysphoria. J Sex Med. 2014;11(3):709–719.
36. Gómez-Gil E, Zubiurre-Elorza L, de Antonio IE, Guillamon A, Salamero M. Determinants of quality of life in Spanish transsexuals attending a gender unit before genital sex reassignment surgery. Qual Life Res. 2014;23(2):669–76.
37. Gómez-Gil E, Vidal-Hagermeijer A, Salamero M. MMPI-2 characteristics of transsexuals requesting sex reassignment: comparison of patients in prehormonal and presurgical phases. J Pers Assess. 2008;80(4):368–74.
38. Heylens G, Verroken C, De Cock S, T'Sjoen G, de Cuypere G. Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J Sex Med. 2014;11(1):119–26.
39. Colizzi M, Costa R, Todarello O. Dissociative symptoms in individuals with
gender dysphoria: is the elevated prevalence real? Psychiatry Res. 2015;
226(1):173–80.
40. Colizzi M, Costa R, Pace V, Todarello O. Hormonal treatment reduces
psychobiological distress in gender identity disorder, independently of the
attachment style. J Sex Med. 2013;10(12):3049–58.
41. Slabbekoorn D, Goozen SHV, Gooren LJ, Cohen-Kettenis PT. Effects of
cross-sex hormone treatment on emotionality in transsexuals. Int J
Transgend. 2001;5(3):2–18.
42. Oda H, Katagami T, Yamada H, et al. Effects of hormonal replacement
therapy on mental state of FTM. Jpn J Sexology. 2011;29:51–7.